City Office REIT Reports First Quarter 2025 Results

VANCOUVER, May 2, 2025 /PRNewswire/ -- City Office REIT, Inc. (NYSE: CIO) (the "Company," "City Office," "we" or "our") today announced its results for the quarter ended March 31, 2025.
First Quarter Highlights
Rental and other revenues were $42.3 million. GAAP net loss attributable to common stockholders was approximately $3.5 million, or ($0.09) per fully diluted share;
Core FFO was approximately $12.3 million, or $0.30 per fully diluted share;
AFFO was approximately $6.5 million, or $0.16 per fully diluted share;
In-place occupancy was 84.9% as of quarter end, or 87.6% including signed leases not yet occupied;
Executed approximately 144,000 square feet of new and renewal leases during the quarter;
Same Store Cash NOI increased 4.4% as compared to the first quarter of 2024;
Declared a first quarter dividend of $0.10 per share of common stock, paid on April 24, 2025; and
Declared a first quarter dividend of $0.4140625 per share of Series A Preferred Stock, paid on April 24, 2025.
Highlights Subsequent to Quarter End
Entered into an agreement with an affiliate of Property Markets Group ("PMG") to redevelop a portion of the Company's City Center property in St. Petersburg, Florida into a planned 49-story residential condominium and mixed-use tower.
"Our first quarter results tracked our expectations," commented James Farrar, the Company's Chief Executive Officer. "We continue to see improving leasing activity and year-over-year strengthening of office real estate fundamentals across our Sun Belt markets. Same Store Cash NOI increased by 4.4% in the first quarter. Similarly, the Company achieved a healthy 8.5% cash re-leasing spread during the last twelve months. We expect that our recent strategic property upgrades will continue to be a positive catalyst for driving leasing results."
"After quarter end, we entered into an agreement with PMG to redevelop the standalone parking garage at our City Center property in St. Petersburg. The development contemplated is a 49-story residential condominium and mixed-use tower that is expected to be marketed under the Waldorf Astoria Residences brand. While presales are expected to commence in the near term, there are significant criteria to be satisfied prior to commencing construction. Regardless, this project and its development entitlements offer tremendous value-creation potential."
A reconciliation of certain non-GAAP financial measures, including FFO, Core FFO, AFFO, NOI, Same Store NOI, Same Store Cash NOI and their equivalent per share measures, to the most directly comparable financial measure under U.S. generally accepted accounting principles ("GAAP") can be found at the end of this release.
Portfolio Operations
The Company reported that its total portfolio as of March 31, 2025 contained 5.4 million net rentable square feet and was 84.9% occupied, or 87.6% including signed leases not yet occupied.
Same Store Cash NOI increased 4.4% for the three months ended March 31, 2025 as compared to the same period in the prior year.
Leasing Activity
The Company's total leasing activity during the first quarter of 2025 was approximately 144,000 square feet, which included 101,000 square feet of new leasing and 43,000 square feet of renewals. Approximately 103,000 square feet of leases signed within the quarter are expected to take occupancy subsequent to quarter end.
New Leasing – New leases were signed with a weighted average lease term of 5.9 years at a weighted average effective annual rent of $29.97 per square foot and at a weighted average cost of $5.60 per square foot per year.
Renewal Leasing – Renewal leases were signed with a weighted average lease term of 5.1 years at a weighted average effective annual rent of $33.87 per square foot and at a weighted average cost of $3.92 per square foot per year.
Capital Structure
As of March 31, 2025, the Company had total principal outstanding debt of approximately $648.1 million. Approximately 82.3% of the Company's debt was fixed rate or effectively fixed rate due to interest rate swaps. City Office's total principal outstanding debt had a weighted average maturity of approximately 1.6 years and a weighted average interest rate of 5.1%.
Real Estate Transactions
On April 14, 2025, the Company entered into a contribution agreement with an affiliate of Property Markets Group ("PMG") to redevelop a portion of the Company's City Center property in St. Petersburg, Florida. PMG is a premier national investment, development and asset management firm focused on large-scale mixed-use residential projects. The parties intend to build an approximately 49-story mixed-use tower containing approximately 70,000 square feet of office space, 15,000 square feet of retail space, and 432,000 square feet of luxury residential condominium units that are expected to be marketed under the Waldorf Astoria Residences brand. Subject to the satisfaction of certain conditions, including financing and presales, the contribution agreement calls for the Company to contribute a parcel of land, including a stand-alone parking garage that services the two office buildings comprising the Company's City Center property, to the partnership. The Company's contribution of land, if it occurs, would provide City Office a 50% interest in the partnership with an affiliate of PMG investing $17 million of cash for its 50% membership interest. Further details can be found in the Company's filing on Form 8-K on April 14, 2025.
On January 14, 2025, the Company completed the previously announced disposition of its Superior Pointe property in Denver, Colorado for a gross sale price of $12.0 million. No gain or loss was recognized on the sale as the property was carried at fair value less cost to sell on the date of disposition.
Dividends
On March 14, 2025, the Company's Board of Directors approved and the Company declared a cash dividend of $0.10 per share of the Company's common stock for the three months ended March 31, 2025. The dividend was paid on April 24, 2025 to common stockholders and unitholders of record as of April 10, 2025.
On March 14, 2025, the Company's Board of Directors approved and the Company declared a cash dividend of $0.4140625 per share of the Company's 6.625% Series A Preferred Stock for the three months ended March 31, 2025. The dividend was paid on April 24, 2025 to preferred stockholders of record as of April 10, 2025.
2025 Outlook
Following the Company's performance for the first quarter of 2025, the Company is reiterating the components of full year 2025 guidance provided in the Company's fourth quarter 2024 earnings press release.
The Company's guidance is based on current plans and assumptions and subject to the risks and uncertainties more fully described in the Company's filings with the United States Securities and Exchange Commission. This outlook reflects management's view of current and future market conditions, including assumptions such as timing and magnitude of future acquisitions and dispositions, if any, rental rates, occupancy levels, leasing activity, our ability to renew expiring leases, uncollectible rents, operating and general administrative expenses, weighted average diluted shares outstanding and rising interest rates. The Company reminds investors that the impacts of the work-from-home trend, inflation and general market conditions are uncertain and impossible to predict. See "Forward-looking Statements" below.
Webcast and Conference Call Details
City Office's management will hold a conference call at 11:00 am Eastern Time on May 2, 2025.
The webcast will be available under the "Investor Relations" section of the Company's website at www.cioreit.com. The conference call can be accessed by dialing 1-833-470-1428 for domestic callers and 1-404-975-4839 for international callers. The passcode for the conference call is 926092.
A replay of the call will be available later in the day on May 2, 2025, continuing through July 31, 2025 and can be accessed by dialing 1-866-813-9403 for domestic callers and 1-929-458-6194 for international callers. The passcode for the replay is 647190. A replay will also be available for twelve months following the call at "Webcasts & Events" in the "Investor Relations" section of the Company's website.
A supplemental financial information package to accompany the discussion of the results will be posted on www.cioreit.com under the "Investor Relations" section.
Non-GAAP Financial Measures
Funds from Operations ("FFO") – The National Association of Real Estate Investment Trusts ("NAREIT") states FFO should represent net income or loss (computed in accordance with GAAP) plus real estate related depreciation and amortization (excluding amortization of deferred financing costs) and after adjustments of unconsolidated partnerships and joint ventures, gains or losses on the sale of property and impairments to real estate.
The Company uses FFO as a supplemental performance measure because the Company believes that FFO is beneficial to investors as a starting point in measuring the Company's operational performance. We also believe that, as a widely recognized measure of the performance of REITs, FFO will be used by investors as a basis to compare the Company's operating performance with that of other REITs.
However, because FFO excludes depreciation and amortization and captures neither the changes in the value of the Company's properties that result from use or market conditions nor the level of capital expenditures and leasing commissions necessary to maintain the operating performance of the Company's properties, all of which have real economic effects and could materially impact the Company's results from operations, the utility of FFO as a measure of the Company's performance is limited. In addition, other equity REITs may not calculate FFO in accordance with the NAREIT definition as the Company does, and, accordingly, the Company's FFO may not be comparable to such other REITs' FFO. Accordingly, FFO should be considered only as a supplement to net income as a measure of the Company's performance.
Core Funds from Operations ("Core FFO") – We calculate Core FFO by using FFO as defined by NAREIT and adjusting for certain other non-core items. We also exclude from our Core FFO calculation acquisition costs, loss on early extinguishment of debt, changes in the fair value of earn-outs, changes in the fair value of contingent consideration and the amortization of stock based compensation.
We believe Core FFO provides a useful metric in comparing operations between reporting periods and in assessing the sustainability of our ongoing operating performance. Other equity REITs may calculate Core FFO differently or not at all, and, accordingly, the Company's Core FFO may not be comparable to such other REITs' Core FFO.
Adjusted Funds from Operations ("AFFO") – We compute AFFO by adding to Core FFO the non-cash amortization of deferred financing fees and non-real estate depreciation, and then subtracting cash paid for recurring tenant improvements, leasing commissions, and capital expenditures, and eliminating the net effect of straight-line rent / expense, deferred market rent and debt fair value amortization. Recurring capital expenditures exclude development / redevelopment activities, capital expenditures planned at acquisition and costs to reposition a property. We exclude certain first generation leasing costs, which are generally to fill vacant space in properties we acquire or were planned at acquisition. We have further excluded all costs associated with tenant improvements, leasing commissions and capital expenditures which were funded by the entity contributing the properties at closing.
Along with FFO and Core FFO, we believe AFFO provides investors with appropriate supplemental information to evaluate the ongoing operations of the Company. Other equity REITs may calculate AFFO differently, and, accordingly, the Company's AFFO may not be comparable to such other REITs' AFFO.
Net Operating Income ("NOI") – We define NOI as rental and other revenues less property operating expenses.
We consider NOI to be an appropriate supplemental performance measure to net income because we believe it provides information useful in understanding the core operations and operating performance of our portfolio.
Same Store Net Operating Income ("Same Store NOI") and Same Store Cash Net Operating Income ("Same Store Cash NOI") – Same Store NOI is calculated as the NOI attributable to the properties continuously owned and operated for the entirety of the reporting periods presented, and Same Store Cash NOI is calculated as Same Store NOI less non-recurring other income, termination fee income, straight-line rent / expense, deferred market rent and the non-controlling interest's share of cash NOI. The Company's definitions of Same Store NOI and Same Store Cash NOI exclude properties that were not stabilized during both of the applicable reporting periods. These exclusions may include, but are not limited to, acquisitions, dispositions and properties undergoing repositioning or significant renovations.
We believe Same Store NOI and Same Store Cash NOI are important measures of comparison because each allows for comparison of operating results of stabilized properties owned and operated for the entirety of both applicable periods and therefore eliminates variations caused by acquisitions, dispositions or repositionings during such periods. Other REITs may calculate Same Store NOI and Same Store Cash NOI differently and our calculation should not be compared to that of other REITs.
Forward-looking Statements
This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Certain statements contained in this press release, including those that express a belief, expectation or intention, as well as those that are not statements of historical fact, are forward-looking statements within the meaning of the federal securities laws and as such are based upon the Company's current beliefs as to the outcome and timing of future events. Forward-looking statements are generally identifiable by use of forward-looking terminology such as "approximately," "anticipate," "assume," "believe," "budget," "contemplate," "continue," "could," "estimate," "expect," "future," "hypothetical," "intend," "may," "outlook," "plan," "potential," "predict," "project," "seek," "should," "target," "will" or other similar words or expressions. There can be no assurance that actual results of forward-looking statements, including projected capital resources, projected profitability and portfolio performance, estimates or developments affecting the Company will be those anticipated by the Company. Examples of forward-looking statements include those pertaining to expectations regarding our financial performance, including under metrics such as NOI and FFO, market rental rates, national or local economic growth, including the impact of inflation, estimated replacement costs of our properties, the Company's expectations regarding tenant occupancy, re-leasing periods, the Company's ability to renew expiring leases, tenant compliance with contractual lease obligations, projected capital improvements, expected sources of financing and ability to service existing financing, expectations as to the likelihood and timing of closing of acquisitions, dispositions, or other transactions, the expected operating performance of the Company's current properties, anticipated near-term acquisitions and descriptions relating to these expectations, including, without limitation, the anticipated net operating income yield and cap rates, lower than expected yields, increased interest rates, operating costs and costs of capital, the Company's expectations regarding the potential City Center development, and changes in local, regional, national and international economic conditions, including as a result of the systemic and structural changes in the demand for commercial office space. Forward-looking statements presented in this press release are based on management's beliefs and assumptions made by, and information currently available to, management.
The forward-looking statements contained in this press release are based on historical performance and management's current plans, estimates and expectations in light of information currently available to us and are subject to uncertainty and changes in circumstances. There can be no assurance that future developments affecting us will be those that we have anticipated. Actual results may differ materially from these expectations due to the factors, risks and uncertainties described above, changes in global, regional or local political, economic, business, competitive, market, regulatory and other factors described in our news releases and filings with the SEC, including but not limited to those described in our Annual Report on Form 10-K for the year ended December 31, 2024 under the heading "Risk Factors" and in our subsequent reports filed with the SEC, many of which are beyond our control. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove to be incorrect, our actual results may vary in material respects from what we may have expressed or implied by these forward-looking statements. We caution that you should not place undue reliance on any of our forward-looking statements. Any forward-looking statement made by us in this press release speaks only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company does not guarantee that the assumptions underlying such forward-looking statements contained in this press release are free from errors. Unless otherwise stated, historical financial information and per share and other data are as of March 31, 2025 or relate to the quarter ended March 31, 2025. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable securities laws.
City Office REIT, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands, except par value and share data)
March 31,
2025December 31,2024
AssetsReal estate propertiesLand
$ 190,372$ 190,372
Building and improvement
1,171,5581,169,793
Tenant improvement
166,374163,569
Furniture, fixtures and equipment
1,4051,3681,529,7091,525,102
Accumulated depreciation
(263,074)(251,956)1,266,6351,273,146
Cash and cash equivalents
21,99718,886
Restricted cash
14,62015,073
Rents receivable, net
52,20852,311
Deferred leasing costs, net
25,57125,291
Acquired lease intangible assets, net
32,77034,631
Other assets
22,72423,744
Assets held for sale
-12,588
Total Assets
$ 1,436,525$ 1,455,670
Liabilities and EquityLiabilities:Debt
$ 645,879$ 646,972
Accounts payable and accrued liabilities
26,96734,535
Deferred rent
6,6247,010
Tenant rent deposits
7,2267,257
Acquired lease intangible liabilities, net
5,9956,301
Other liabilities
17,29416,879
Liabilities related to assets held for sale
-2,176
Total Liabilities
709,985721,130
Commitments and ContingenciesEquity:6.625% Series A Preferred stock, $0.01 par value per share, 5,600,000 shares authorized,
4,480,000 issued and outstanding as of March 31, 2025 and December 31, 2024
112,000112,000
Common stock, $0.01 par value, 100,000,000 shares authorized, 40,358,240 and 40,154,055
shares issued and outstanding as of March 31, 2025 and December 31, 2024
403401
Additional paid-in capital
442,578442,329
Retained earnings
172,218179,838
Accumulated other comprehensive loss
(1,359)(713)
Total Stockholders' Equity
725,840733,855
Non-controlling interests in properties
700685
Total Equity
726,540734,540
Total Liabilities and Equity
$ 1,436,525$ 1,455,670
City Office REIT, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except per share data)
Three Months Ended March 31,20252024
Rental and other revenues
$ 42,258$ 44,493
Operating expenses:Property operating expenses
16,27217,744
General and administrative
3,7283,711
Depreciation and amortization
15,12515,075
Total operating expenses
35,12536,530
Operating income
7,1337,963
Interest expense:Contractual interest expense
(8,278)(8,098)
Amortization of deferred financing costs and debt fair value
(354)(319)(8,632)(8,417)
Net loss
(1,499)(454)
Less:Net income attributable to non-controlling interests in properties
(171)(135)
Net loss attributable to the Company
(1,670)(589)
Preferred stock distributions
(1,855)(1,855)
Net loss attributable to common stockholders
$ (3,525)$ (2,444)
Net loss per common share:Basic
$ (0.09)$ (0.06)
Diluted
$ (0.09)$ (0.06)
Weighted average common shares outstanding:Basic
40,30640,097
Diluted
40,30640,097
Dividend distributions declared per common share
$ 0.10$ 0.10
City Office REIT, Inc.
Reconciliation of Net Income to FFO, Core FFO and AFFO
(Unaudited)
(In thousands, except per share data)
Three Months Ended
March 31, 2025
Net loss attributable to common stockholders
$ (3,525)
(+) Depreciation and amortization
15,12511,600
Non-controlling interests in properties:(+) Share of net income
171
(-) Share of FFO
(338)
FFO attributable to common stockholders
$ 11,433
(+) Stock based compensation
914
Core FFO attributable to common stockholders
$ 12,347
(+) Net recurring straight-line rent/expense adjustment
50
(-) Net amortization of above and below market leases
(3)
(+) Net amortization of deferred financing costs and debt fair value
352
(-) Net recurring tenant improvements and incentives
(2,918)
(-) Net recurring leasing commissions
(1,539)
(-) Net recurring capital expenditures
(1,793)
AFFO attributable to common stockholders
$ 6,496
FFO per common share
$ 0.27
Core FFO per common share
$ 0.30
AFFO per common share
$ 0.16
Dividends distributions declared per common share
$ 0.10
FFO Payout Ratio
36 %
Core FFO Payout Ratio
34 %
AFFO Payout Ratio
64 %
Weighted average common shares outstanding - diluted
41,586
City Office REIT, Inc.
Reconciliation of Rental and Other Revenues to Same Store NOI and Same Store Cash NOI
(Unaudited)
(In thousands)
Three Months Ended March 31,20252024
Rental and other revenues
$ 42,258$ 44,493
Property operating expenses
16,27217,744
Net operating income ("NOI")
$ 25,986$ 26,749
Less: NOI of properties not included in same store
(42)(676)
Same store NOI
$ 25,944$ 26,073
Less:Termination fee income
(15)(912)
Straight-line rent/expense adjustment
30(304)
Above and below market leases
(3)(23)
NCI in properties – share in cash NOI
(471)(426)
Same store cash NOI
$ 25,485$ 24,408
ContactCity Office REIT, Inc.Anthony Maretic, CFO+1-604-806-3366investorrelations@cityofficereit.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/city-office-reit-reports-first-quarter-2025-results-302444485.html
SOURCE City Office REIT, Inc.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

27 minutes ago

• Business Wire

EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit

Yahoo

40 minutes ago

• Yahoo

Axiom Intelligence Acquisition Corp 1 Announces Completion of $200 Million Initial Public Offering

New York, New York, June 20, 2025 (GLOBE NEWSWIRE) -- Axiom Intelligence Acquisition Corp 1 (NASDAQ:AXINU) (the 'Company') today announced the closing of its initial public offering of 20,000,000 units, which includes 2,500,000 units sold pursuant to the partial exercise of the underwriters' over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $200,000,000. The Company's units commenced trading on the Nasdaq Global Market ('Nasdaq') under the symbol 'AXINU' on June 18, 2025. Each unit issued in the offering consists of one Class A ordinary share of the Company and one right to receive one tenth (1/10) of one Class A ordinary share upon the consummation of the Company's initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on Nasdaq under the symbols 'AXIN' and 'AXINR,' respectively. The Company is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any stage of its corporate evolution or in any industry or sector, the Company intends to focus its initial search on companies in the European infrastructure industry. The Company's management team is led by Richard Dodd, its Executive Chairman, Douglas Ward, its Chief Executive Officer, Daniel Mamadou-Blanco, its President, Robert Dilling, its Chief Financial Officer, and Chris Ackermann, its Chief Operating Officer. Dr. Claire Handby, Steven Leighton and Christopher Ellis are the Company's independent directors and Sankalp Shangari and Wendy Li are its senior advisers. Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC, acted as the lead book-running manager for the offering. Seaport Global Securities LLC acted as joint book-runner. A registration statement relating to the units and the underlying securities was declared effective by the Securities and Exchange Commission on June 17, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of a prospectus, copies of which may be obtained from Cohen & Company Capital Markets, 3 Columbus Circle, 24th Floor, New York, NY 10019, Attention: Prospectus Department, or by email at: capitalmarkets@ Copies of the registration statement can be accessed for free through the SEC's website at Forward-Looking Statements This press release contains statements that constitute 'forward-looking statements,' including with respect to the anticipated use of the net proceeds of the offering and the Company's search for an initial business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and final prospectus for the offering filed with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law. Contact Information: Axiom Intelligence Acquisition Corp 1Richard Dodd, Executive Chairman / Doug Ward, Chief Executive Officercontact@ +44 20 3973 7928

Business Wire

2 hours ago

• Business Wire

OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association's 85th Scientific Sessions

MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio, Inc. ('OrsoBio' or 'the Company'), a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new preclinical data being presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) being held June 20-23, 2025, in Chicago, Ill. The Company will present three abstracts highlighting the efficacy of its mitochondrial protonophores to induce weight loss and provide glycemic benefits while preserving lean mass in diet-induced obese (DIO) mice. The studies demonstrate the potential of TLC-6740 and TLC-1180—as monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide—for both the induction and maintenance of weight loss following incretin treatment. 'The mechanism of our mitochondrial protonophores to increase energy expenditure complements that of incretins to enhance and sustain weight loss and provide additive metabolic benefits,' said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio. 'These preclinical findings mark an important step in fulfilling our mission to develop innovative, effective, oral therapies for obesity that preserve muscle and support cardiometabolic health.' OrsoBio is advancing a pipeline of novel therapies targeting obesity through mechanistically distinct and complementary approaches. The Company's lead candidates include TLC-6740 and TLC-1180, both mitochondrial protonophores that promote weight loss by increasing energy expenditure. In addition, OrsoBio is developing TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), designed to enhance fat oxidation. "GLP-1 receptor agonists have transformed obesity treatment but are limited by gastrointestinal side effects and loss of muscle mass,' said Rob Myers, MD, Chief Medical Officer of OrsoBio. 'Our preclinical data show that our mitochondrial protonophores drive sustained, fat-selective weight loss and metabolic benefits when combined with or sequenced after GLP-1 receptor agonists. These findings support our ongoing Phase 1b study of TLC-6740 in combination with tirzepatide (NCT05822544)." Poster information: Sequential Combination of the Mitochondrial Protonophore TLC-6740 With Semaglutide Normalizes Body Weight and Preserves Lean Mass in DIO Mice Abstract #1687-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study assessed TLC-6740 alone, in combination with low-dose semaglutide (sequential combination), and as maintenance therapy following semaglutide discontinuation in DIO mice. The sequential combination of TLC-6740 with low-dose semaglutide produced superior body weight and fat mass loss, and improved glycemic parameters compared with TLC-6740 alone and high-dose semaglutide. Initiating TLC-6740 after semaglutide discontinuation maintained body weight and fat mass loss, and glycemic benefits. These findings support evaluation of TLC-6740 in combination with incretins in people living with obesity; a 24-week combination study of TLC-6740 with tirzepatide is ongoing (NCT05822544). De Novo or Sequential Combination of the Mitochondrial Protonophore TLC-1180 With Semaglutide Improves Weight Loss and Preserves Lean Mass in DIO Mice Abstract #1694-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of TLC-1180 alone, in combination with semaglutide, and as a maintenance treatment following semaglutide discontinuation in DIO mice. As monotherapy, TLC-1180 demonstrated body weight and fat mass loss and preserved lean mass. Body weight and fat mass loss were amplified, and lean mass was preserved with TLC-1180 in combination with semaglutide. These benefits persisted when TLC-1180 was used as a maintenance treatment after semaglutide discontinuation. These data highlight the potential of TLC-1180 as monotherapy, in combination with incretins, or as maintenance therapy post incretin discontinuation in people living with obesity. Novel Combination of a Mitochondrial Protonophore and an Acetyl-CoA Carboxylase 2 (ACC2) Inhibitor Causes Weight Loss and Preserves Lean Mass in Obese Mice Abstract #1686-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of the mitochondrial protonophore, TLC-1180, and the ACC2 inhibitor, TLC-3595—as monotherapy and in combination—and semaglutide in DIO mice. TLC-3595 dose dependently reduced body weight, fat mass, and liver biochemistry while preserving lean mass in DIO mice. A combination of TLC-3595 with TLC-1180 had similar weight loss efficacy to semaglutide, but preserved lean mass. Taken together, these data suggest that the novel, all-oral, non-incretin combination of TLC-3595 and TLC-1180 may cause similar weight loss to incretins and may afford additional advantages, including improved weight loss quality and/or tolerability (e.g., reduced incidence of gastrointestinal adverse events). About TLC-6740 TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and MASH. Based on active hepatic uptake and mitochondrial protonophore activity, TLC-6740 increases energy expenditure in hepatocytes, and is expected to have broad, systemic metabolic and cardiovascular benefits, including weight loss, improved insulin sensitivity, and as a treatment for MASH, and dyslipidemia. TLC-6740 is currently being evaluated in a Phase 1b clinical trial, as monotherapy and in combination with tirzepatide, in patients living with obesity (NCT05822544). About TLC-1180 TLC-1180 is a novel, potent, long-acting mitochondrial protonophore that has been shown to increase energy expenditure in mice with diet-induced obesity (DIO). In preclinical studies of DIO mice, TLC-1180 induced weight loss, improved glucose control, and enhanced the efficacy of GLP-1 receptor agonists, both as a single agent and in combination with incretins. TLC-1180 is currently completing IND-enabling studies and a first-in-human study is expected to initiate in 2025. About TLC-3595 TLC-3595 is a novel and selective ACC2 inhibitor designed to treat obesity and type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver. The compound may also have potential as a treatment for other conditions characterized by impaired FAO, including heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatohepatitis (MASH). About OrsoBio, Inc. OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. For more information, please visit